Tao Y, Kim J, Yin Y, Zafar I, Falk S, He Z, Faubel S, Schrier R W, Edelstein C L
Department of Internal Medicine, Texas Tech University Health Sciences Center, Amarillo, Texas 79106, USA.
Kidney Int. 2007 Dec;72(11):1358-66. doi: 10.1038/sj.ki.5002550. Epub 2007 Sep 19.
Although the receptors for vascular endothelial growth factor (VEGF) exert their effects on vasculogenesis and angiogenesis through receptors located on endothelial cells, recent studies have shown that these receptors are also present on renal tubular epithelial cells. We investigated the role of VEGF on increased tubule cell proliferation in the Han:SPRD heterozygous (Cy/+) rat model of polycystic kidney disease. The levels of VEGF in the kidneys and the serum, and the expression of the two receptors on tubules were increased in Cy/+ rats. These rats were given ribozymes that specifically inhibited VEGFR1 and VEGFR2 mRNA expression. Tubule cell proliferation within the cysts was significantly decreased in the ribozyme-treated animals leading to decreased cystogenesis, blunted renal enlargement, and prevented the loss of renal function. Our studies show that inhibition of VEGF function may be an important therapeutic option to delay the progression of polycystic kidney disease.
尽管血管内皮生长因子(VEGF)的受体通过位于内皮细胞上的受体对血管生成和血管新生发挥作用,但最近的研究表明,这些受体也存在于肾小管上皮细胞上。我们在Han:SPRD杂合子(Cy/+)多囊肾病大鼠模型中研究了VEGF在肾小管细胞增殖增加中的作用。Cy/+大鼠肾脏和血清中的VEGF水平以及肾小管上两种受体的表达均增加。给这些大鼠注射特异性抑制VEGFR1和VEGFR2 mRNA表达的核酶。在接受核酶治疗的动物中,囊肿内的肾小管细胞增殖显著减少,导致囊肿形成减少、肾脏肿大减轻,并防止了肾功能丧失。我们的研究表明,抑制VEGF功能可能是延缓多囊肾病进展的重要治疗选择。